

595 eligible patients included in the clinical trial

FFPE tissue samples available:
n = 367 (62% of the patients)

Insufficient tumor tissue on sections

At least one value for HER2 or TOP2A available:
n = 352 (96% of the FFPE blocks)

Template abundance, method eligibility
criteria

CISH analysis

HER2 n=285 (81%)
TOP2A n=266 (76%)
HER2/TOP2A n=266 (76%)

qRT-PCR (mRNA expression)

HER2 n=314 (89%)
TOP2A n=314 (89%)
HER2/TOP2A n=314 (89%)

IHC analysis

HER2 n=297 (84%)
Topolla n=273 (78%)
HER2/Topolla n=269 (76%)

Profiled HER2 variables

HER2 CISH/mRNA n=249 (70%)
HER2 CISH/IHC n=278 (79%)
HER2 mRNA/IHC n=261 (74%)
HER2, all n=243 (69%)

Profiled TOP2A variables

TOP2A CISH/mRNA n=232 (66%)
TOP2A CISH/IHC n=249 (70%)
TOP2A mRNA/IHC n=240 (68%)
TOP2A, all n=217 (62%)